Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

BMC Cancer

Research Article

Keita Mori¹  Ryo Koyama²  Fumiyuki Takahashi²  Ryota Kanemaru²  Rina Shibayama²  Naoko Shimada²  Yasuhito Sekimoto²  Hiroaki Ihara²  Ryo Ko²  Takehito Shukuya²  Kazuhisa Takahashi²  Ken Tajima²  Shinichi Sasaki³  Kota Nakamura³  Motoyasu Kato³  Osamu Nagashima³ 

[1] Clinical Trial Coordination Office, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, 411-8777, Suntou-gun, Shizuoka, Japan;Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 3-1-3, Hongo, Bunkyo-ku, 113-8431, Tokyo, Japan;Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 3-1-3, Hongo, Bunkyo-ku, 113-8431, Tokyo, Japan;Department of Respiratory Medicine, Juntendo University Urayasu Hospital, 2-1-1, Tomioka, 273-0021, Urayasu, Chiba, Japan;

关键词: Interstitial lung disease;    Drug-induced interstitial lung disease;    Lung cancer;   

DOI  :  10.1186/s12885-017-3285-6

 received in 2016-12-26, accepted in 2017-04-19,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundInterstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarkers sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), and clinical characteristics in patients diagnosed with ILD-AA.MethodsBetween April 2011 and March 2016, 1224 advanced lung cancer patients received cytotoxic agents and epidermal growth factor receptor tyrosine kinase inhibitors at Juntendo University Hospital and Juntendo University Urayasu Hospital. Of these patients, those diagnosed with ILD-AA were enrolled in this case control study. ΔKL-6 and ΔSP-D were defined as the difference between the levels at the onset of ILD-AA and their respective levels prior to development of ILD-AA. We evaluated KL-6 and SP-D at the onset of ILD-AA, ΔKL-6 and ΔSP-D, the risk factors for death related to ILD-AA, the chest high resolution computed tomography (HRCT) findings, and survival time in patients diagnosed with ILD-AA.ResultsThirty-six patients diagnosed with ILD-AA were enrolled in this study. Among them, 14 patients died of ILD-AA. ΔSP-D in the patients who died was significantly higher than that in the patients who survived. However, ΔKL-6 did not differ significantly between the two groups. Moreover, ΔSP-D in patients who exhibited diffuse alveolar damage was significantly higher than that in the other patterns on HRCT. Receiver operating characteristic curve analysis was used to set the optimal cut off value for ΔSP-D at 398 ng/mL. Survival time for patients with high ΔSP-D (≥ 398 ng/mL) was significantly shorter than that for patients with low ΔSP-D. Multivariate analysis revealed that ΔSP-D was a significant prognostic factor of ILD-AA.ConclusionsThis is the first research to evaluate high ΔSP-D (≥ 398 ng/mL) in patients with ILD-AA and to determine the risk factors for ILD-AA in advanced lung cancer patients. ΔSP-D might be a serum prognostic biomarker of ILD-AA. Clinicians should evaluate serum SP-D during chemotherapy and should carefully monitor the clinical course in patients with high ΔSP-D.

【 授权许可】

CC BY   
© The Author(s). 2017